To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

Phase 1

Completed

• Conditions: Healthy Adult
• Interventions: Drug: SGLT2 inhibitor

• Registration Number: NCT06165965
• Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Brief Summary

To evaluate the safety and pharmacokinetic characteristics after the administration of JT-001, JT-002 and JLP-2008

Detailed Description

A randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of JLP-2008 and the co-administration of JT-001, and JT-002 for healthy subjects in fasted state

Study Timeline

• Study Start: 2022-05-03
• Primary Completion: 2022-06-13
• Study Completion: 2022-06-27
• Status Verified: 2023-11
• Study First Submitted: 2023-11-22
• Study First Submitted QC: 2023-12-07
• Last Update Submitted: 2023-12-07
• Study First Posted: 2023-12-12
• Last Update Posted: 2023-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Healthy adults between 19 and 55 years of age at the time of screening test
2. At the time of the screening test, a subject weighing more than 50 kg for men and 45 kg for women, and a body mass index (BMI) of 18.0 kg/m2 or more and 30.0 kg/m2 or less.
3. After receiving a detailed explanation of this clinical trial and fully understanding it, those who voluntarily decide to participate and give written consent before the screening procedure

Exclusion Criteria

1. Those with a clinically significant history of hypersensitivity, intolerance, or anaphylaxis to the main ingredient or other components of the investigational product

2. Those who have clinically siginificant medical history of liver (severe liver disorders, etc.), kidneys (severe renal disorders, etc.), digestive system (pancreatitis, etc.), respiratory system, musculoskeletal system, endocrine system (diabetic ketoacidosis, diabetic coma and precoma, type 1 Diabetes mellitus), neuropsychiatric, hematologic/oncological, and cardiovascular (heart failure, orthostatic hypotension, etc.)

3. Those with a history of Gastrointestinal disease (e.g. Crohn's disease, ulcerative disease, etc.) or surgery (excluding appendectomy, hernia surgery, endoscopic polyp surgery, hemorrhoids, dentition, and fistula surgery) that may affect the absorption of the investigational product

4. Persons judged to be unsuitable as trial subjects in the test items conducted during screening

   • Blood ALT, AST, Total bilirubin > 2 times the upper limit of normal range
   • eGFR < 60 mL/min/1.73m2 (using CKD-EPI formula)
   • HBsAg, HCV Ab, HIV, Syphilis regain test (RPR) results are positive
   • Vital signs measured in the sitting position after resting for more than 3 minutes: systolic blood pressure > 160 mmHg or < 90 mmHg, or diastolic blood pressure > 100 mmHg or < 50 mmHg

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Treatment(Experimental): JLP-2008	SGLT2 inhibitor	- Group I(Peroid I-Comparator\[JT-001,JT-002\], Peroid II-JLP-2008), Group II(Period I-JLP-2008, Period II-Comparator\[JT-001,JT-002\])
Control(Active Comparator): JC-013	SGLT2 inhibitor	- Group I(Peroid I-Comparator\[JT-001,JT-002\], Peroid II-JLP-2008), Group II(Period I-JLP-2008, Period II-Comparator\[JT-001,JT-002\])

Primary Outcome Measures

Name	Time	Method
Cmax of JLP-2008	24 hours
AUC over24H of JLP-2008	24 hours

Trial Locations

Locations (1)

Bundang CHA university global clinical trials center Institutional Review Board; 🇰🇷 Gyeonggi-do, Bundang-gu, Korea, Republic of